Linked Life Data

7682735

Source:http://linkedlifedata.com/resource/pubmed/id/7682735

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1993-5-20
pubmed:abstractText
Heterotopic hamster hearts transplanted to unmodified LEW rats underwent humoral rejection in 3 days. Survival was prolonged to a median of 4 days with 2 mg/kg/day FK506. As monotherapy, 15 mg/kg/day cyclophosphamide greatly prolonged graft survival--far more than could be accomplished with RS-61443, brequinar (BQR), mizoribine, methotrexate, or deoxyspergualin. However, when FK506 treatment, which was ineffective alone, was combined with a short induction course (14 or 30 days) of subtherapeutic BQR, RS-61443, or cyclophosphamide, routine survival of heart xenografts was possible for as long as the daily FK506 was continued. In addition, a single large dose of 80 mg/kg cyclophosphamide 10 days preoperatively allowed routine cardiac xenograft survival under FK506. The ability of these antimetabolites to unmask the therapeutic potential of FK506 correlated, although imperfectly, with the prevention of rises of preformed heterospecific cytotoxic antibodies immediately postoperatively. As an adjunct to FK506, azathioprine was of marginal value, whereas mizoribine, methotrexate, and deoxyspergualin (DSPG) were of intermediate efficacy. After orthotopic hepatic xenotransplantation, the perioperative survival of the liver with its well-known resistance to antibodies was less dependent than the heart on the antimetabolite component of the combined drug therapy, but the unsatisfactory results with monotherapy of FK506, BQR, RS-61443, or cyclophosphamide were changed to routine success by combining continuous FK506 with a short course of any of the other drugs. Thus, by breaking down the antibody barrier to xenotransplantation with these so-called antiproliferative drugs, it has been possible with FK506 to transplant heart and liver xenografts with consistent long-term survival of healthy recipients.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0041-1337
pubmed:author
pubmed:issnType
Print
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
701-7; discussion 707-8
pubmed:dateRevised
2010-12-3
pubmed:meshHeading
pubmed-meshheading:7682735-Animals, pubmed-meshheading:7682735-Antibody Formation, pubmed-meshheading:7682735-Antilymphocyte Serum, pubmed-meshheading:7682735-Biphenyl Compounds, pubmed-meshheading:7682735-Cricetinae, pubmed-meshheading:7682735-Cyclophosphamide, pubmed-meshheading:7682735-Drug Synergism, pubmed-meshheading:7682735-Drug Therapy, Combination, pubmed-meshheading:7682735-Fluorescent Antibody Technique, pubmed-meshheading:7682735-Follow-Up Studies, pubmed-meshheading:7682735-Graft Rejection, pubmed-meshheading:7682735-Graft Survival, pubmed-meshheading:7682735-Heart Transplantation, pubmed-meshheading:7682735-Immunoglobulin A, pubmed-meshheading:7682735-Immunoglobulin M, pubmed-meshheading:7682735-Immunosuppressive Agents, pubmed-meshheading:7682735-Liver Transplantation, pubmed-meshheading:7682735-Male, pubmed-meshheading:7682735-Mesocricetus, pubmed-meshheading:7682735-Mycophenolic Acid, pubmed-meshheading:7682735-Rats, pubmed-meshheading:7682735-Splenectomy, pubmed-meshheading:7682735-Tacrolimus, pubmed-meshheading:7682735-Transplantation, Heterologous
pubmed:year
1993
pubmed:articleTitle
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs.
pubmed:affiliation
Pittsburgh Transplant Institute, University of Pittsburgh Health Science Center, Pennsylvania 15213.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.